Matthew C Winter
Overview
Explore the profile of Matthew C Winter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
316
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parker V, Winter M, Tidy J, Palmer J, Sarwar N, Singh K, et al.
Gynecol Oncol
. 2023 Dec;
180:152-159.
PMID: 38091775
Objective: The International Federation of Gynecology and Obstetrics (FIGO) scoring system uses the sum of eight risk-factors to predict single-agent chemotherapy resistance in Gestational Trophoblastic Neoplasia (GTN). To improve ease...
2.
Singh K, Ireson J, Rollins S, Gillett S, Ronksley J, Winter M
Eur J Oncol Nurs
. 2023 Dec;
68:102481.
PMID: 38043171
Purpose: We aimed to explore patient's experience of chemotherapy-induced menopausal symptoms; to ascertain how patients tried to alleviate their symptoms and how health professionals supported them in order to identify...
3.
Parker V, Baker Z, Stone B, Singh K, Winter M, Palmer J
AIDS
. 2023 Oct;
38(1):69-73.
PMID: 37816174
Objective: To assess the HIV prevalence in patients diagnosed with gestational trophoblastic neoplasia (GTN). Design: A retrospective single centre cohort study. Methods: A database from the Sheffield Trophoblastic Disease Centre...
4.
Ring A, Kilburn L, Pearson A, Moretti L, Afshari-Mehr A, Wardley A, et al.
Clin Cancer Res
. 2023 Sep;
29(23):4751-4759.
PMID: 37773077
Purpose: Approximately 10% to 15% of triple-negative breast cancers (TNBC) have deleterious mutations in BRCA1 and BRCA2 and may benefit from PARP inhibitor treatment. PARP inhibitors may also increase exogenous...
5.
Winter M, Tidy J, Singh K, Sarwar N, Aguiar X, Seckl M
Gynecol Oncol
. 2023 Jun;
175:66-71.
PMID: 37327541
Background: Approximately one-third of patients with low-risk Gestational Trophoblastic Neoplasia (WHO 0-6) develop methotrexate-resistance (MTX-R). In the UK, subsequent treatment with either actinomycin-D (ActD) or multi-agent combination chemotherapy has depended...
6.
Parker V, Cushen B, Hills A, Kandiah K, Palmer J, Singh K, et al.
Gynecol Oncol
. 2022 Dec;
169:34-40.
PMID: 36495594
Background: Single-agent methotrexate (MTX) is commonly used as first-line treatment for low-risk gestational trophoblastic neoplasia (LR-GTN), although no international consensus exists on the optimal treatment regimen to maximise complete hCG...
7.
Parker V, Winter M, Tidy J, Hancock B, Palmer J, Sarwar N, et al.
Int J Cancer
. 2022 Nov;
152(5):986-997.
PMID: 36346113
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is...
8.
Battisti N, Hatton M, Reed M, Herbert E, Morgan J, Bradburn M, et al.
Radiother Oncol
. 2021 Jun;
161:166-176.
PMID: 34146616
Background: Radiotherapy reduces in-breast recurrence risk in early breast cancer (EBC) in older women. This benefit may be small and should be balanced against treatment effect and holistic patient assessment....
9.
Ring A, Battisti N, Reed M, Herbert E, Morgan J, Bradburn M, et al.
Br J Cancer
. 2021 May;
125(2):209-219.
PMID: 33972747
Background: Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is infrequently offered to older individuals. This study determined if there are fit older patients with high-risk...
10.
Winter M
Best Pract Res Clin Obstet Gynaecol
. 2021 Mar;
74:67-80.
PMID: 33741258
Low-risk gestational trophoblastic neoplasia (GTN), defined as FIGO/WHO score 0-6, is highly curable with an overall survival rate, which is approximately 100%. For most low-risk GTN patients, first-line single-agent chemotherapy...